SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. ~~20549 ______________________~~ 20549______________________

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

Pursuant to Rule 13a-16 or 15d-16 of ~~the Securities~~theSecurities Exchange Act of 1934

For the month of ~~May~~August 2025

Commission File Number: 001-36349

MediWound Ltd. (Translation of registrant’s name into English)

42 Hayarkon Street

Yavne, 8122745 Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

~~EXPLANATORY NOTE~~CONTENTS

OnResults ~~May~~of ~~21,~~Operations ~~2025,~~and ~~MediWound~~Financial ~~Ltd.~~Condition— ~~(the “Company”) issued a press release entitled “MediWound Reports First~~ Quarter ~~2025 Financial Results~~ and ~~Provides~~Six ~~Corporate~~Months ~~Update”.~~Ended AJune ~~copy~~30, ~~of this press release is attached to this Form 6-K as Exhibit 99.1.~~2025

~~The~~On ~~contents~~August of14, ~~this~~2025, ~~Report~~MediWound ofLtd. ~~Foreign Private Issuer on Form 6-K~~ (~~including~~“MediWound” ~~the~~or ~~information contained in Exhibit 99.1, but excluding quotes of senior management of~~ the “Company”) ~~are~~ ~~hereby~~issued ~~incorporated~~a bypress ~~reference~~release ~~into~~entitled ~~the~~“MediWound ~~Company’s~~Reports ~~Registration~~Second ~~Statements~~Quarter on2025 ~~Form~~Financial ~~S-8~~Results ~~filed~~and ~~with~~Provides ~~the~~Company ~~SEC on April 28~~Updates,” ~~2014,~~in ~~March~~which ~~24,~~MediWound ~~2016,~~reported ~~March~~its ~~19,~~results ~~2018,~~of ~~March~~operations. ~~25,~~A ~~2019,~~copy ~~February~~of ~~25,~~that ~~2020,~~press ~~May~~release ~~15,~~is ~~2021~~attached ~~August~~to 9,this ~~2022,~~Report ~~August~~of ~~15,~~Foreign ~~2023,~~Private ~~and March~~Issuer ~~19, 2025 (Registration Nos. No. 333-195517, 333-210375, 333-223767, 333-230487, 333-236635, 333-255784, 333-266697, 333-273997 and 333-285897, respectively) and~~ on Form F6-3K ~~filed with the SEC on March 31, 2023, August 29, 2024 and March 19, 2025~~ (~~Registration~~this ~~Nos.~~“Form ~~333~~6-~~268297,~~K”) ~~333-281843~~as ~~and~~Exhibit ~~333-285908, respectively)~~99.1.

Attached hereto, as Exhibit 99.2 to this Form 6-K, is MediWound's financial statements, as of, and for the quarter and six months ended on, June 30, 2025.

Attached hereto as Exhibit 101 are the financial statements of MediWound as of, and for the quarter and six months ended on, June 30, 2025, formatted in XBRL (eXtensible Business Reporting Language), consisting of the sub-exhibits listed in the exhibit table below.

Exhibits

Exhibit
Number		Exhibit Description
99.1		Press release reporting MediWound’s financial results
99.2		Financial statements, as of, and for the quarter and six months ended on, June 30, 2025
EX-101.INS		XBRL Taxonomy Instance Document
EX-101.SCH		XBRL Taxonomy Extension Schema Document
EX-101.CAL		XBRL Taxonomy Calculation Linkbase Document
EX-101.DEF		XBRL Taxonomy Extension Definition Linkbase Document
EX-101.LAB		XBRL Taxonomy Label Linkbase Document
EX-101.PRE		XBRL Taxonomy Presentation Linkbase Document

Incorporation by Reference

The contents of this Report of Foreign Private Issuer on Form 6-K (including the information contained in Exhibits 99.1 and 99.2, but excluding quotes of senior management of the Company), are hereby incorporated by reference into the Company’s Registration Statements on Form S-8 filed with the SEC on April 28, 2014, March 24, 2016, March 19, 2018, March 25, 2019, February 25, 2020, May 5, 2021, August 9, 2022 , August 15, 2023, and March 19, 2025 (Registration Nos. No. 333-195517, 333-210375, 333-223767, 333-230487, 333-236635, 333-255784, 333-266697, 333-273997 and 333-285897, respectively) and on Form F-3 filed with the SEC on March 31, 2023, August 29, 2024 and March 19, 2025 (Registration Nos. 333-268297, 333-281843 and 333-285908, respectively).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: ~~May~~August 2114, 2025 MEDIWOUND LTD. By: /s/ Hani Luxenburg Name: Hani Luxenburg Title: Chief Financial Officer

~~EXHIBIT INDEX~~4

The following exhibit is filed as part of this Form 6-K:

Exhibit Description

99.1 Press release dated May 21, 2025 titled “MediWound Reports First Quarter 2025 Financial Results and Provides Corporate Update”.

Filing Compare · MediWound Ltd.